
Mantle Cell Lymphoma
Latest News
Latest Videos

CME Content
More News

The FDA has eliminated REMS programs for BCMA- and CD19-directed autologous CAR T-cell therapies approved for multiple myeloma and select types of lymphoma/leukemia.

Alexey Danilov, MD, PhD, discussed how chemotherapy-free regimens have influenced treatment decision-making for patients with mantle cell lymphoma.

Brad S. Kahl, MD, discusses the evolving role of BTK inhibitors in the mantle cell lymphoma treatment paradigm.

The FDA updated the labels for liso-cel and ide-cel to reduce monitoring select requirements and remove REMS programs for the CAR T-cell therapies.

Alexey Danilov, MD, PhD, shares key developments and areas of debate from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.

R2 followed by R-DHAP led to an ORR of 93.3% in patients with newly diagnosed MCL.

Acalabrutinib plus BR prolonged duration of MRD negativity vs BR alone in previously untreated MCL, supporting the use of MRD as a prognostic biomarker.

Ibrutinib plus venetoclax led to complete responses and durable remissions in the first-line treatment of older patients with MCL.

CHMP recommended ibrutinib plus immunochemotherapy for previously untreated, transplant-eligible mantle cell lymphoma.

Treatment with ibrutinib plus venetoclax and a CD20 monoclonal antibody induced high MRD negativity rates vs ibrutinib/anti-CD20 in untreated MCL.

The FDA has approved a tablet formulation of zanubrutinib for use in all 5 approved indications of the capsule formulation.

Experts highlight key abstracts to watch for at the 2025 EHA Congress.

Findings from a matching-adjusted indirect comparison showed a PFS benefit with zanubrutinib vs orelabrutinib in relapsed/refractory mantle cell lymphoma.

Brad Kahl, MD, discusses the ongoing unmet needs in the treatment of mantle cell lymphoma.

Brad S. Kahl, MD, explains the importance of identifying less intensive induction regimens for older patients with mantle cell lymphoma.

Martin Dreyling, MD, discusses the patient population studied in the TRIANGLE trial of ASCT plus ibrutinib-containing therapy in younger patients with MCL.

Patients with MCL and large clonal hematopoiesis clones experienced shortened PFS and OS vs those without clones.

Brad S. Kahl, MD, details the evaluation of induction BR plus bortezomib with rituximab/lenalidomide maintenance in mantle cell lymphoma.

Timothy S. Fenske, MD, MS, discusses the rationale for evaluating the role of standard auto-HCT in MCL given recent updates to the MCL treatment paradigm.

Early progression or death within 24 months of first-line treatment was linked to inferior survival in mantle cell lymphoma.

The European Commission has approved acalabrutinib plus bendamustine and rituximab for previously untreated, transplant-ineligible mantle cell lymphoma.

On-site adaptive manufacturing of LV20.19 resulted in a high complete response rate and favorable tolerability in relapsed/refractory mantle cell lymphoma.

Treatment with the IR2 regimen led to durable responses that were favorable compared with those in chemotherapy-treated relapsed/refractory MCL.

Patients with MCL who received real-world brexu-cel experienced lower survival when they were BTK inhibitor refractory and/or had lower platelet counts.



















































